SCHEMBL4777976

SCHEMBL4777976

N#Cc1cc(Nc2cccc(Cl)c2)c2cc(F)ncc2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FADS1 O60427 3/20 0.43
SYK P43405 1/20 0.43
EGFR P00533 8/20 0.42
ERBB2 P04626 3/20 0.42
PTGS1 P23219 1/20 0.40
PTGS2 P35354 1/20 0.40
MAOB P27338 1/20 0.38
GRM5 P41594 1/20 0.38
LCK P06239 1/20 0.38
PDGFRB P09619 1/20 0.37
PDGFRA P16234 1/20 0.37
ADORA2A P29274 1/20 0.37
PTK6 Q13882 1/20 0.37
TDO2 P48775 1/20 0.37
CTSV O60911 1/20 0.37
PLAT P00750 1/20 0.37
CTSL P07711 1/20 0.37
CTSH P09668 1/20 0.37
CTSS P25774 1/20 0.37
CASP14 P31944 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4775748 0.87 MAPKAPK2 (0.45) EGFRPTGS1PTGS2CNR2
SCHEMBL4767004 0.84 ABCG2 (0.43) EGFR
SCHEMBL4776121 0.84 KCNQ3 (0.39) SYKEGFRERBB2PTGS2TDO2
SCHEMBL4767045 0.82 MAP2K1 (0.46) EGFRERBB2PDGFRB
SCHEMBL4776048 0.82 NPC1 (0.41) SYKEGFRERBB2PTGS1PTGS2
SCHEMBL4769765 0.80 SLC2A1 (0.42) SYKEGFRERBB2PTGS1PTGS2
SCHEMBL4769773 0.77 MAP2K1 (0.44) CNR2
SCHEMBL4766924 0.77 ABCB1 (0.39) MAOB
SCHEMBL4767089 0.77 EGFR (0.66) EGFRERBB2
SCHEMBL4768795 0.74 CYP11B2 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7432279-B2 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same WYETH (US) 2008-10-07 US disclosed
EP-1881981-A1 4, 6-DIAMINO-[1,7] NAPHTHYRIDINE-3-CARBONITRILE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME Wyeth (US) 2008-01-30 EP disclosed
US-20060276498-A1 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same WYETH (US) 2006-12-07 US disclosed
WO-2006124944-A1 4, 6-DIAMINO-[1,7] NAPHTHYRIDINE-3-CARBONITRILE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276498-A1 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same TNNI3K, CNKSR1, DTYMK FADS1 4169/4885SYK 1191/4885EGFR 2871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.